UK-based medical equipment developer CMR Surgical has raised $100m in a Series B funding round to support the commercialisation of its next-generation surgical robotic system Versius.

The new financing came from Zhejiang Silk Road Fund and the company’s existing investors Escala Capital Investments, Watrium, LGT and Cambridge Innovation Capital.

CMR Surgical said it will use the fresh funds to complete the validation studies required for the regulatory approval processes of the Versius system in Europe and the US.

“The compact and portable Versius system has been designed to meet the complex requirements of laparoscopic surgery.”

The company is also planning for international expansion and commercial scale-up to cater to the robot-assisted minimal access surgery market, which is expected to touch $20bn by 2025.

CMR Surgical CEO Martin Frost said: “CMR Surgical’s rapid growth has given us the opportunity to develop a life-changing solution which we expect to change the take up of minimal access surgery worldwide.

“With these latest funds, we intend to start commercialising Versius in Europe, the USA and more broadly.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Founded in 2014, CMR Surgical focuses on developing robotic solutions for minimal access surgery and helping numerous people who undergo open surgery each year.

The compact and portable Versius system has been designed to meet the complex requirements of laparoscopic surgery.

The system can easily fit into hospital workflows and its ergonomic console design will alleviate surgeons’ physical and mental effort, the company added.

Currently, the system is being studied in pre-clinical trials for its ability to perform gastrointestinal, gynaecological, colorectal and renal surgeries.